• Delivering first-in-human clinical findings from the world’s inaugural autophagy-targeting degrader for neurodegenerative disease
• Demonstrating safety, pharmacokinetics, and exposure outcomes from single- and multiple-ascending dose studies to validate clinical feasibility
• Advancing formulation and translational development of ATB2005A in canine dementia models to strengthen cross-species proof-of-concept and accelerate therapeutic advancement

Clinical Update